OSTAAT™ is a non-invasive connected medical device for people affected by osteopenia and osteoporosis, associated or not by severe chronic kidney disease.

The technology involves applying a low-intensity electric current with no side effects. The current acts on cell membrane mechanisms, allowing calcium to enter the cells, thus promoting bone growth.

The technology can be used preventively, to reduce the risk of fractures of all kinds, or curatively, to accelerate the healing process of fractures* caused by osteoporosis, severe chronic kidney disease, or other conditions.

* Claims will be addressed in future clinical trials.

A SOLUTION TO AN UNMET NEED

KAT Innovation's OSTAAT™ technology addresses an unmet need for over 850 million people worldwide suffering from chronic kidney disease (CKD), with over 135 million affected by severe CKD. This population has a high prevalence of osteoporosis, for which drug treatments are contraindicated. Consequently, due to bone resorption, their bones become brittle, significantly increasing the risk of fractures and mortality associated with this comorbidity.

In response to this challenging situation affecting a significant portion of the population, KAT Innovation offers an accessible and easy-to-use technology that finally meets an unmet need for these patients.

SCIENTIFIC EVIDENCE

The OSTAAT™ device transmits a gentle electrical current of very low intensity. This unique and patented* current, developed by university researchers, has undergone proof of concept studies to understand its mode of action on bone growth. These studies include both in vitro experiments and clinical investigations.

* Patents pending.

Learn more

Our president's involvement in a separate research project has so far uncovered a link between electrical stimulation and bone growth. This information prompted an exhaustive review of the scientific literature by our team of researchers, under the direction of our scientific leader Mr. Roland Savard, Ph.D., physiologist, and professor at UQAM and our chief medical officer, Dr Ramzi Bouzidi, orthopedist surgeon. This review specifically focused on the relationship between electrical stimulation and bone formation processes. The synthesis of this literature review has given rise to new hypotheses that are currently being studied in collaboration with university researchers through in vitro studies and clinical studies.

One of these collaborations, supervised by our Chief Scientist, is in partnership with Professor Tatiana Scorza, and her master's student Arleth Pozo of UQAM's Department of Biological Sciences.

Launched in November 2022, a first in vitro study confirmed one of the initial hypotheses concerning the link between the application of electrical stimulation, according to rigorously defined parameters, and the bone formation process. These results allow us to specify the electrical current parameters of our device — protected by a patent — and constitute the basis of our technology.

The findings of this research will soon be disseminated to the public through a presentation at a scientific congress and a scientific publication in an internationally renowned journal. This is a pivotal step in our research and proof-of-concept journey. We are now ready to move forward to the next step — a multi-center clinical study.

OSTAAT™ vs DRUGS

The electrical stimulation OSTAAT™ does not cause any side effects, muscle contractions, or unpleasant physical sensations.

However, taking medication is often accompanied by side effects. Some of these side effects can have serious repercussions, such as osteonecrosis of the jaw and atypical fractures.

A DEVICE ACCESSIBLE TO ALL

At the cutting edge of technology, the OSTAAT™ device in its prototype belt version for clinical studies and its smart clothing version, will be able to be activated via a mobile app accessible on cell phone, tablet, or computer.

FUTURE CLINICAL STUDIES

Since August 2022, we have initiated our first scientific studies in collaboration with various international partners.

A first in vitro study, conducted in partnership with UQAM's Department of Biological Sciences, began in early August 2022 under the direction of Professor Tatiana Scorza. This research is in line with one of our key objectives: to address different scientific hypotheses concerning the mechanisms of technology and the fundamental functioning of bone growth.

We also plan to conduct human clinical studies in collaboration with various partners, including the McGill University Health Centre (Research Institute), the CHU de Québec in Canada, the CHU de Bordeaux, Poitiers, and Limoges in France, as well as the CHU of Malaga and Granada in Spain, not to mention the Mongi Slim Hospital in Tunisia. Simultaneously, negotiations are underway to involve physicians from England and the United States.

An in vivo study involving animals is also central to our scientific approach.